二次性TDP-43蛋白病变的发生率和形态:第二部分
Albert Acewicz1, Tomasz Stępień1, Paulina Felczak1
1Department of Neuropathology, Institute of Psychiatry and Neurology, Warsaw, Poland.
Folia neuropathologica
|August 17, 2023
概括
交换激活 (TAR) DNA结合蛋白 43 kDa (TDP-43) 病理在罕见的神经退行性疾病和非退行性神经疾病中很常见. 了解TDP-43的共同病理对于诊断和治疗至关重要.
科学领域:
- 神经病理学神经病理学
- 神经退行性疾病 神经退行性疾病
- 蛋白质病变是一种蛋白质病变.
背景情况:
- 交换激活 (TAR) DNA 结合蛋白 43 kDa (TDP-43) 含有在各种神经退行性疾病的共患.
- TDP-43病理也发生在非退行性神经疾病中,如瘤,副瘤,创伤或传染病因.
- 在神经退行症中,TDP-43和其他病理蛋白之间的相互作用仍然不完全理解.
研究的目的:
- 审查TDP-43病理的发生率,形态和作用.
- 在二次TDP-43蛋白病症的背景下研究TDP-43.
- 在审查的第二部分中,专注于罕见的神经退行性疾病和非退行性神经疾病.
主要方法:
- 关于神经病理学研究的文献评论.
- 在各种神经疾病中分析TDP-43病理.
- 综合关于共同病理及其影响的发现.
主要成果:
- 在罕见的神经退行性疾病和非退行性神经疾病中,TDP-43病理是显著的特征.
- 同时出现的TDP-43与其他病理会加剧大脑缩和临床严重程度.
- 本综述 (第二部分) 详细介绍了TDP-43在较少发病的神经疾病中的作用.
结论:
- TDP-43蛋白病变与一系列神经系统疾病有关,包括罕见和非退行性疾病.
- 识别TDP-43共同病理对于准确的死前诊断和有效的治疗策略至关重要.
- 需要进一步研究TDP-43相关神经退行症背后的机制.
更多相关视频
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015
8.8K
11:03Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
7.3K
相关概念视频
03:03Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
01:26Alzheimer's Disease: Overview
518
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
518